264 related articles for article (PubMed ID: 33315067)
1. Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies.
Alzahabi KH; Usmani O; Georgiou TK; Ryan MP; Robertson BD; Tetley TD; Porter AE
Emerg Top Life Sci; 2020 Dec; 4(6):581-600. PubMed ID: 33315067
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
4. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
5. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
6. Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.
Braunstein M; Hickey AJ; Ekins S
Pharm Res; 2019 Oct; 36(12):166. PubMed ID: 31650321
[TBL] [Abstract][Full Text] [Related]
7. Autophagy Induction as a Host-Directed Therapeutic Strategy against
Adikesavalu H; Gopalaswamy R; Kumar A; Ranganathan UD; Shanmugam S
Medicina (Kaunas); 2021 May; 57(6):. PubMed ID: 34070995
[TBL] [Abstract][Full Text] [Related]
8. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
9. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
10. Inhaled drug delivery for tuberculosis therapy.
Muttil P; Wang C; Hickey AJ
Pharm Res; 2009 Nov; 26(11):2401-16. PubMed ID: 20183916
[TBL] [Abstract][Full Text] [Related]
11. Infection caused by Mycobacterium tuberculosis.
Peloquin CA; Berning SE
Ann Pharmacother; 1994 Jan; 28(1):72-84. PubMed ID: 8123968
[TBL] [Abstract][Full Text] [Related]
12. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
13. TMC207: the first compound of a new class of potent anti-tuberculosis drugs.
Matteelli A; Carvalho AC; Dooley KE; Kritski A
Future Microbiol; 2010 Jun; 5(6):849-58. PubMed ID: 20521931
[TBL] [Abstract][Full Text] [Related]
14. Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection.
Dwivedi VP; Bhattacharya D; Singh M; Bhaskar A; Kumar S; Fatima S; Sobia P; Kaer LV; Das G
J Ethnopharmacol; 2019 Oct; 243():111634. PubMed ID: 30537531
[TBL] [Abstract][Full Text] [Related]
15. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Multidrug-resistant Tuberculosis.
Rumende CM
Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.
Ahsan MJ; Ansari MY; Yasmin S; Jadav SS; Kumar P; Garg SK; Aseri A; Khalilullah H
Infect Disord Drug Targets; 2015; 15(1):32-41. PubMed ID: 25246035
[TBL] [Abstract][Full Text] [Related]
18. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
Singh J; Garg T; Rath G; Goyal AK
Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
[TBL] [Abstract][Full Text] [Related]
19. Focus on perchlozone, an anti-tuberculosis drug from the Russian Federation.
Malík I; Čižmárik J; Pecháčová M
Ceska Slov Farm; 2020; 69(5-6):203-210. PubMed ID: 33736445
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
